

# pevion

B I O T E C H

virosome-based vaccine design

## COMPANY PROFILE


Pevion Biotech is a privately owned Swiss biopharmaceutical company founded in 2002 as an industrial spin-off of Crucell N.V. (former Berna Biotech AG) and Bachem AG. The company's mission is to develop efficient and safe vaccines using an established vaccine platform and the corresponding industrial development process. The virosome-based technology is validated by two registered and marketed products. Pevion Biotech will develop products to clinical Phases I/II, thereafter licensing to partners for further development, registration, marketing and sales. The development pipeline includes, among others, vaccines against hepatitis C, breast cancer and malaria. Located in Bern, Switzerland, the company currently has a highly qualified staff of 21.

## VIROSOME TECHNOLOGY PLATFORMS

Pevion Biotech uses the technology platforms PeviPRO™ and PeviTER™ for the development of a new generation of prophylactic and therapeutic vaccines. Virosomes are spherical unilamellar synthetic lipid vesicles possessing influenza virus surface glycoproteins. These virosomes retain natural fusogenic characteristics, thus mimicking a virus, but they lack the viral ability to reproduce. Together with an antigen of choice, these virosomes are able to evoke a specific and strong immune response without having significant side-effects. Depending on the localization of the antigen, the virosomes are able to evoke a humoral (PeviPRO™) and/or a cellular (PeviTER™) immune response. Two virosome-based vaccines have already been approved by registration authorities in more than 45 countries, and over 26 million patients have been immunized so far.

◆ Pevion Biotech is a leading specialist in the development of innovative virosome-based vaccines. Decisive success factors are an accelerated development process in accordance with industrial standards of the market-approved technology. ◆

## PRODUCT PIPELINE



## INTELLECTUAL PROPERTY

The objective of Pevion Biotech's strict IP policy is to protect every aspect of the three technology platforms, as well as every single product in development. Currently, Pevion Biotech has more than six patent applications filed and holds exclusive licenses on several granted patents.

## FINANCIAL SUMMARY

The joint venture partners – each holding a 50% stake – have provided a total of CHF 20 million as start-up capital. In Q3/2007 Pevion Biotech closed a CHF 35 million (about EUR 22 million, USD 27 million) Series A private financing round. The round was led by the new investor BZ Bank Aktiengesellschaft. New investors joining the Series A also include BB Biotech Ventures II, L.P. and CC Private Equity Partners Ltd. The existing investor Bachem also participated in this financing round.

## PARTNERING OPPORTUNITIES

Many epitopes of pathogens are known today. These epitopes are often weak immunogens, and it is important to introduce them into the immune system in such a way that a specific and strong immune response is induced while the resulting vaccine is still safe and well tolerated. The two technology platforms PeviPRO™ and PeviTER™ make it possible to formulate a given epitope with virosomes and integrate it into Pevion Biotech's standardized vaccine development process. Our expertise in vaccine development, together with the appropriate resources (e.g. GMP pilot facility for the production of PeviPRO™ and PeviTER™ formulated vaccines), provides the opportunity for an accelerated and product-oriented development through clinical Phase I/II. Further development, industrialized production, registration, marketing and sales can be pursued by the licensee himself or by one of our partners. In both cases, licensees can rely on Pevion Biotech's complete and structured state-of-the-art documentation, including analytical test methods, low-scale GMP manufacturing procedures, necessary GLP, a toxicology study package and a GCP Phase I/II package. This guarantees our licensees a fast and continuous development process.

## EXECUTIVE BOARD

Peter Klein	CEO Pevion Biotech AG
Dr. Rinaldo Zurbriggen	CSO Pevion Biotech AG
Dr. Thomas Stauffer	COO Pevion Biotech AG

## BOARD OF DIRECTORS

Dr. Peter Grogg	Chairman of the Board, President Bachem Holding AG
Dr. Kuno Sommer	Vice Chairman of the Board, CBO Crucell AG
Dr. Joseph Manko	Member of the Board, BZ Bank
Dr. Klaus Breiner	Member of the Board BB Biotech
Dr. Daniel Erne	Member of the Board, CTO Bachem Holding AG

## SCIENTIFIC ADVISORY BOARD

Prof. Albert Osterhaus	Professor of Virology, Medical Faculty, Erasmus University Hospital, Rotterdam
Prof. Antonio Lanzavecchia	Director of the Institute for Research in Biomedicine, Bellinzona
Prof. Alan Gewirtz	Professor of Internal Medicine University of Pennsylvania
Prof. Josef Brunner	Professor Emeritus of Biochemistry, Institute of Biochemistry, Swiss Federal Institute of Technology, Zurich



Pevion Biotech Ltd.  
Rehlagstrasse 79  
CH-3018 Bern  
Switzerland  
Phone +41 31 980 62 03  
Fax +41 31 980 66 18  
info@pevion.com  
www.pevion.com

